Chiappini S

Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Health, Medicine and Life Sciences, University of Hertfordshire, AL10 9AB, Hertfordshire, UK; UniCamillus International University of Medical Sciences, Via di S. Alessandro 8, Rome, Italy. Electronic address: stefaniachiappini9@gmail.com.

13 papers · ORCID

ArticleKetamine

Treatment and management approaches for ketamine misuse: A systematic review of medical interventions.

Mosca A, Chiappini S, Miuli A +9

Europe PMC2026
ArticlePsychedelics

Substance-Specific Treatment Responses and Resistance Patterns in Induced Psychoses: A Scoping Review of Antipsychotic Efficacy.

Ricci V, Chiappini S, Martinotti G +1

Europe PMC2025
ArticleKetamine

Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.

d'Andrea G, Chiappini S, Ciavoni L +13

Europe PMC2025
ArticleKetamine

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective.

Chiappini S, Guirguis A, Schifano N +9

Europe PMC2025
ArticleKetamine

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.

d'Andrea G, Pettorruso M, Di Lorenzo G +16

Europe PMC2024
ArticleKetamine

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).

Pettorruso M, Guidotti R, d'Andrea G +25

Europe PMC2023
ArticleKetamine

Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.

d'Andrea G, Chiappini S, McIntyre RS +12

Europe PMC2023
ArticleKetamine

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.

Chiappini S, d'Andrea G, De Filippis S +10

Europe PMC2023
ArticleKetamine

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.

Martinotti G, Dell'Osso B, Di Lorenzo G +23

Europe PMC2023
ArticleIbogaine

Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.

Mosca A, Chiappini S, Miuli A +8

Europe PMC2023
ArticlePsychedelics

The Benzydamine Experience: A Systematic Review of Benzydamine Abuse.

Chiappini S, Miuli A, Mosca A +6

Europe PMC2021
ArticleKetamine

Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.

Martinotti G, Chiappini S, Pettorruso M +8

Europe PMC2021
ArticleAyahuasca

How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy.

Orsolini L, Chiappini S, Papanti D +6

Europe PMC2020